antifungal therapy 230210.ppt [read-only] · non-linear kinetics: saturable metabolism! • small...
TRANSCRIPT
![Page 1: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/1.jpg)
ANTIFUNGAL AGENTS
Katrien Lagrou
![Page 2: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/2.jpg)
0
1
2
3
4
5
6
7
8
1980 1985 1990 1995 1997
Dea
ths
per 1
00,0
00 p
opul
atio
n
Trends in mortality due to invasive mycosis in the US
0-4
5-24
25-44
45-64
≥65
McNeil et al., Clin Infect Dis, 2001: 33, 641-7
![Page 3: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/3.jpg)
The fungal ‘players’• Opportunistic fungi
– Normal flora• Candida spp.
– Ubiquitous in our environment• Aspergillus spp.• Cryptococcus spp.• Mucor spp.
• Newly emerging fungi- Fusarium spp.- Scedosporium spp.
• Endemic geographically restricted- Blastomyces spp.- Coccidioides spp.- Histoplasma spp.
![Page 4: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/4.jpg)
Risk factors for candidemia• Prolonged stay in ICU• Use of broad spectrum antibiotics • Abdominal surgery • Candida colonization (>2 sites)• Central venous and urinary catheters• Total parenteral nutrition• Renal failure (hemodialysis)• Immunosuppression (underlying condition,
immunosuppressive agents)• Intravenous drug use• Severe pancreatitis• Prematurity in neonates
![Page 5: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/5.jpg)
General risk factors for invasive aspergillosis
Major• Neutropenia (+ monocytopenia)• Corticosteroid treatment
Minor• CD4penia• Inherited immunodeficiency (i.e. CGD)• Lung or sinus damage/disease• Severe liver disease• Exposure to high inocula
New• Genetic risk assessment• TLR, INF, MBL, IL-10, ….
![Page 6: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/6.jpg)
Invasive fungal infections in adult HSCT recipientsSpecies distribution for IFI in HSCT recipients 2004-2007
59%25%
7% 9%
Aspergillus CandidaZygomycetes Others
71%
25%
4%Aspergillus Candida Others
Neofytos et al. CID 2009; 48: 265 Pagano et al. CID 2007; 45: 1161
![Page 7: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/7.jpg)
02468
101214
1950 1960 1970 1980 1990 2000
Nysta
tinAm
phot
erici
nB
(195
8)
Griseo
fulvi
n
5-FCMiconazole
KetoconazoleFluconazole
Itraconazole
L-AmBABCDABLC
Terbinafine
Voriconazole
Posaconazole
Cas
pofu
ngin
MicafunginIsavuconazole
Ani
dula
fung
in
![Page 8: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/8.jpg)
Mannoproteins
β-(1→6)-glucan
β-(1→3)-glucan
ChitinPhospholipid bilayer of cellmembrane
Ergosterol
Ergosterolsynthesispathway
AZOLES
POLYENES
β-(1→3)-glucan synthaseECHINOCANDINS
Squalene
ALLYLAMINES
FLUOROPYRIMIDINES
DNA/RNA synthesis
![Page 9: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/9.jpg)
Antifungal agents active on fungal cell membrane
![Page 10: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/10.jpg)
Classic amphotericin B deoxycholate formulation is a colloidal suspension of amphotericin B. A bile salt, deoxycholate, is used as the solubilizing agent.
Amphotericin B deoxycholate
![Page 11: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/11.jpg)
Binds to sterols (preferentially ergosterol)
↓Disruption osmotic integrity
of fungal membrane ↓
Leakage of intracellular components
↓Fungal death
![Page 12: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/12.jpg)
Amphotericin B: Spectrum and Recommended Dose• Spectrum:
• Very broad, active against most fungi except Aspergillusterreus, Scedosporium, Trichosporon and Candida lusitaniae (Candida glabrata)
• Fungicidal
• Amphotericin B: 1 mg/kg IV (after a test dose of 1 mg)
• Lipid-based Amphotericin B
• amphotericin B lipid complex (ABLC): 5 mg/kg IV
• liposomal amphotericin B (L-Amb): 3 mg/kg IV
![Page 13: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/13.jpg)
Amphotericin B: Pharmacokinetics
• No oral bioavailability• Undetectable in CSF (but mainstay for
treatment of Cryptococcal meningitis)• Highly (>90%) protein bound • Exact routes of metabolism (minor hepatic)
and elimination (feces) are largely unknown• Half-life: 24-48 h
![Page 14: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/14.jpg)
Amphotericin B: Tolerability and Safety
• Chills, rigors, fever (during infusion)• Nausea, vomiting• Phlebitis• Nephrotoxicity: incidence: 49-65%• Hypokalemia
can be explained by mode of action: ampho B binds cholesterol in distal tubular membrane leading to wasting of Na+, K+ and Mg++
![Page 15: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/15.jpg)
Amphotericin B: Tolerability and Safety
• Acute renal failure = contra-indication• Can be used in patients with irreversible
terminal renal failure on hemodialysis →renal elimination only 20% of total clearance → low risk of accumulation
• No dose adjustment in patients with hepatic failure
• No risk for the fetus (↔ azoles)
![Page 16: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/16.jpg)
• amphotericin B lipid complex: phospholipid ribbons(1.6-11µm)
• amphotericin B colloidal dispersion:cholesteryl sulfate complex(0.12-0.14 µm)
• liposomal amphotericin B(0.08 µm)
![Page 17: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/17.jpg)
Lipid-Formulated amphotericin B:pharmacokinetics
L-Amb ABLC
Cmax 83.0 mg/L 1.7 mg/L
Toxicity 20 mg/kg: minimal nephrotoxicity (rats)
10 mg/kg: mild nephrotoxicity (rats)
Mode of action Liposome targeting to fungal cell wall with release of AMB into fungus
Release of AMB from complexes by phospholipases?
Drug localisation –therapeutic effect
Comparable efficacy to ABLC even with lower tissue concentrations
Higher concentrations in lung, liver and spleenTaken primarily up by tissues of RES
![Page 18: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/18.jpg)
Amphotericin B: Pharmacodynamics
• Time-kill kinetics in vitro: concentration-dependent fungicidal activity against Candida, Cryptococcus and A. fumigatus
• PK/PD relationship in vivo associated with effective therapy:AMB: Cmax/MIC 4-10L-AMB: Cmax/MIC >40
Lewis, Curr Opinion Pharmacol 2007; 7:491-497
![Page 19: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/19.jpg)
AZOLES
1. Imidazoles
2. Triazoles
(1979)
Voriconazole
![Page 20: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/20.jpg)
![Page 21: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/21.jpg)
Active (cidal) against
Aspergillusspp.
Newer triazolesbetter activity (static)
against Candida spp.
No activity againstZygomycetes except
posaconazole
![Page 22: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/22.jpg)
Fluconazole: PharmacokineticsBio-availability - > 80%
- not dependent of gastric pH or food: IV-PO switch possible!
Distribution - extensive: Vd 0.7-1.0 L/kg- protein binding: 11%- CSF levels: >70% of plasma levels- good penetration in bone
Metabolism - minor hepaticExcretion - mainly renal: dose reduction in severe renal failure
- removed by dialysis- reliable urine concentrations- half-life: 27-34 hrs
Charlier C. JAC 2006; 57:384-410.
![Page 23: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/23.jpg)
Fluconazole: drug interactions
Inhibits CYP2C9, CYP2C19 and CYP3A4• cyclosporine: TDM• midazolam: excessive sedation• phenytoin: TDM• tacrolimus: TDM• warfarin: monitor INR
Rifampin induces fluconazole metabolism:• increase fluconazole dose with 25%
Charlier C. JAC 2006; 57:384-410.
![Page 24: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/24.jpg)
• Generally very well tolerated• Side effects occur especially in high doses (>400
mg/day)– Common: headache, nausea, abdominal pain,
alopecia– Elevated AST/ALT levels: generally mild
• Reported in 10% of leukemia patients with fluconazole prophylaxis• Reported in 20% of ICU patients with fluconazole prophylaxis
– Rare: case reports of fulminant hepatitis– Very rare: neurotoxicity (high doses > 1200 mg/day)
Charlier C. JAC 2006; 57:384-410.
Fluconazole: Tolerability and Safety
![Page 25: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/25.jpg)
Voriconazole: PharmacokineticsBio-availability >90% on empty stomach (↓ with food)Steady state - 5-6 days
- loading dose necessary!Distribution - extensive (Vd: 4.6 L/kg)
- CSF concentration ~ 50% of plasma concentration- vitreal penetration 38%- protein binding 58%
Metabolism - hepatic (CYP2C19, CYP3A4, CYP2C9)
Elimination -80% via urine-20% via feces-Half-life: 6h
![Page 26: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/26.jpg)
Non-linear kinetics: saturable metabolism!• Small increases in dose result in exponential
increases in blood levels• In children: linear pharmacokinetics, higher
metabolizing capacity
Purkins L et al. AAC 2002; 46:2546-53.
Voriconazole serum levels: high interindividualvariability: difficult pharmacokinetics!
![Page 27: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/27.jpg)
Voriconazole: Interindividual variability
Genetic polymorphism CYP2C19• 3 genotypes: extensive metabolizers,
heterozygous extensive metabolizers, poor metabolizers
• PM especially in Asian population: 18-23%• PM in Caucasian population: 3-5%• Plasma levels up to 2-fold (HM) or 4-fold (PM)
higher!
![Page 28: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/28.jpg)
Voriconazole: PharmacokineticsExtensive CYP-metabolism: drug interactions!
• Other drugs affecting voriconazole plasma levels– Contra-indicated with potent inducers
» Rifampin, ritonavir, carbamazepine, phenobarbital– Dose adjustments needed if combined with phenytoin
and rifabutin (↑ 5 mg/kg bid)• Voriconazole affecting plasma levels of others (inhibition)
– Contra-indicated with sirolimus, terfenadine, astemizole, cisapride, …
– Dose adjustments needed if combined with» Cyclosporine: TDM» Tacrolimus: TDM
![Page 29: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/29.jpg)
• Visual disturbances: (20%)• Altered perception of light, photophobia, blurred vision, color
vision changes: mechanism unknown• Transient, infusion related• More in patients with higher levels
• Hepatotoxicity (13%)• AST, ALT, alkaline phosphatases, bilirubin elevations• Correlating with higher vorico plasma levels
• Phototoxicity (6%): erythema, Steven-Johnson syndrome, toxic epidermal necrolysis
• Neurological changes: confusion and hallucinations
Voriconazole: Safety
![Page 30: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/30.jpg)
• IV vials contain sulphobutylether-[beta]-cyclodextrin, a solubilizer
• In patients with moderate to severe renal failure (CrCl < 50 ml/min): accumulation of SBECD →oral therapy if possible!
• In patients on intermittent dialysis therapy• No toxic effects observed• Systematic monitoring of the level of consciousness,
hemodynamic stability, dermal reactions, and liver function tests required
Von Mach MA et al. BMC Clin Pharamacol 2006; 6:6
Voriconazole: Nephrotoxicity of SBECD
![Page 31: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/31.jpg)
• Loading dose: 2 x 6 mg/kg• Maintenance dose: 2 x 4 mg/kg• Child A and B cirrhosis (Child C: no data)
– Loading dose idem– Maintenance dose: 2 x 2 mg/kg
• Children (2-12 yrs)– 2 x 7 mg/kg
Voriconazole: Recommended doses
![Page 32: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/32.jpg)
Pascual A. CID 2008;46:201-211.
Voriconazole: Therapeutic Drug Monitoring
52 adult patients: 181 samples
25%: levels < 1 mg/L
31%: levels ≥ 5.5 mg/L
31% CNS toxicity19% hepatitis
![Page 33: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/33.jpg)
• Consensus and specific recommendations not yet available but accumulating evidence that TDM may play an important role in optimizing the safety and efficacy
• Supported by IDSA in selected cases
• Subset of patients need to be defined:e.g. Children, patients with a high BMI, abnormal liver function, drug-drug
interactions, patients with marked toxicity
• Validated assay necessary• Plasma through levels preferred, provisional therapeutic
range: 1-6 mg/L• Frequent monitoring after dose adjustments is warranted
Walsh et al. ,CID, 2008, 46: 327-60.
Voriconazole: Therapeutic Drug Monitoring
![Page 34: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/34.jpg)
Bio-availability - 52-100%- Dependent on dosing frequency and intake with meal (↑ with high-fat meal)- Saturation in absorption if daily dose > 800 mg
Distribution - Extensive (Vd ~ 25 L/kg)- Tissue penetration: limited data- Protein binding > 98%
Metabolism - Hepatic: metabolized as glucuronide conjugates
Elimination - Majority via feces as unchanged drug- Minimal renal elimination (14%)- Half-life 35 hr
Schiller D et al. Clin Ther 2007; 29: 1862-1886
Posaconazole: Pharmacokinetics
![Page 35: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/35.jpg)
• Posaconazole inhibits CYP3A4• Tacrolimus: TDM (dose reduction)• Cyclosporine: TDM (dose reduction)• Increase in serum concentrations of benzodiazepines,
calcium channel blockers, statines,…
• Posaconazole is substrate of uridine diphosphate-glucuronosyltransferase
• Induction by phenytoin: contra-indicated!• Induction by rifabutin: contra-indicated! (+ rifabutin levels
increased)
Schiller D et al. Clin Ther 2007; 29: 1862-1886
Posaconazole: Drug Interactions
![Page 36: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/36.jpg)
• Dosing in patients with hepatic impairment?• Posaconazole should be used with caution• Not studied using Child score
• Dosing in patients with renal impairment?• Dose adjustment not necessary• Drug is not cleared with hemodialysis
Schiller D et al. Clin Ther 2007; 29: 1862-1886
Goodwin M et al. JAC 2008, 61:17-25.
Posaconazole: Pharmacokinetics
![Page 37: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/37.jpg)
• Seems to be more favorable compared to voriconazole
• Headaches (8%)• Gastro-intestinal side effects: abdominal pain,
diarrhea, nausea: 3-12%• Elevated liver function tests and hepatotoxicity
(<3%)• Rash• Hypokalemia
Posaconazole: Tolerability and Safety
Schiller D et al. Clin Ther 2007; 29: 1862-1886
Goodwin M et al. JAC 2008, 61:17-25.
![Page 38: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/38.jpg)
• Available only as a suspension for oral use• Treatment:
• 400 mg 2x/day with food or nutritional supplement• 200 mg 4x/day if no intake of food
• Prophylaxis: 200 mg 3x/day
Posaconazole: Recommended Doses
![Page 39: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/39.jpg)
Triazoles: Pharmacodynamics
• Time-kill kinetics in vitro: • Concentration-independent fungistatic activity
against Candida, Cryptococcus • Time-dependent and concentration-dependent
fungicidal activity against A. fumigatus
• PK/PD relationship in vivo associated with effective therapy: AUC/MIC ≥ 25 (Candida spp.)
Lewis, Curr Opinion Pharmacol 2007; 7:491-497
![Page 40: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/40.jpg)
Antifungal agents active on fungal cell wall
![Page 41: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/41.jpg)
Phospholipid bilayerof the fungal cell
membrane
Fungalcell wall
β-(1,3)-glucan
β-(1,6)-glucan
β-(1,3)-glucan synthaseErgosterol
![Page 42: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/42.jpg)
PK is specific for each echinocandin
HO
NH
O
HO
OH
HN
O
N
H3C
HO
H3C
HO
NH
O
HN
CH3
OH
N
O
OOH
O
NH
O
HO OH
O
H3C
NO
NHO
HO
HO
NH
O
OH
HN
H2N
OH
H2N
O
OH
HN
OH
HO
H
H
H HNH O
H
CH3
OHO NH
O
H3C
CH3 CH3
caspofungin HO
O
NH
O
HO
OH
HN
O
N
HO
H2N
O
H3C
HO
NH
O
HN
CH3
OH
N
O
OOH
O
NH
O
O
N
HO OH
O
H3C
S
OH
O
O
micafunginanidulafungin
Sidechain determines:‐ Activity: interaction with the cell wall‐Farmacokinetics: more lipophilic→ higher distribution volume
ECHINOCANDINS
![Page 43: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/43.jpg)
Active (static) against
Aspergillus spp.
Active (cidal) against
Candida spp.
![Page 44: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/44.jpg)
Bio-availability <2%: only IVDistribution -Protein binding: 96%, no elimination via dialysis
-Linear pharmacokinetics-Good distribution into most tissues (minimal urine, CSF, brain and ocular fluid penetration)
Metabolism - Hepatic: hydrolysis and N-acetylation: no active metabolites- not CYP450 dependent
Excretion -Via urine and feces (only 2% unchanged)-Half-life: 9-11h
Caspofungin: Pharmacokinetics
![Page 45: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/45.jpg)
• No dose adjustments in renal insufficiency• No CYP-mediated metabolism
• No CYP-mediated drug interactions• No genetic polymorphisms
• Uptake via hepatic transporter: OATP• OATP= organic anion transporting polypeptide• Reduced uptake in patients with hepatic insufficiency
• Dose reduction in Child B liver cirrhosis• No recommendations in Child C
• Drug interactions mediated by OATP?Sandhu P et al. DMD 2005; 33: 676-82.
Caspofungin: Pharmacokinetics
![Page 46: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/46.jpg)
OATP = organic anion transporting polypeptide
• drug uptake transporter
•Basolateral membrane of hepatocytes
•Contributes to overall elimination of caspofungin
• Cyclosporine and rifampin are also substrates for OATP1B1
Caspofungin: Pharmacokinetics
![Page 47: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/47.jpg)
• Co-administration with cyclosporine• AUC caspo + 25%• Competitive inhibition at OATP?
• Co-administration with rifampin• Inhibition and induction effect on caspofungin• First days: rifampin blocks uptake by OATP• After continued dosing: rifampin induces OATP• Net effect: AUC caspo ↓: increase MD to 70mg/day
• Other inducers: efavirenz, nevirapine, dexamethasone, phenytoin, carbamazepine– Increase MD to 70 mg/day
Caspofungin: Pharmacokinetics
![Page 48: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/48.jpg)
• Excellent safety and tolerability• Can be explained by mode of action: human
cells do not have a cell wall
• Adverse events = unspecific drug reactions• Histamine-mediated: headache, fever, nausea• Elevation of hepatic enzyme levels
• AST, ALT and ALP• < 5-fold ULN
Caspofungin: Tolerability and Safety
![Page 49: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/49.jpg)
• Loading dose: 70 mg• Maintenance dose: 50 mg
• Patients > 80 kg: 70 mg
• Child B liver cirrhosis• Loading dose: 70 mg• Maintenance dose: 35 mg
• Children: 3 months-17 year• LD: 70 mg/m2/d, MD: 50 mg/m2/d
• Infants < 3 months• LD: 25 mg/m2/d, MD: 25 mg/m2/d
Caspofungin: Recommended Dose
![Page 50: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/50.jpg)
Anidulafungin MicafunginBio-availability
Low, only IV administration Low, only IV administration
Distribution - Vd: 0.57 L/kg- Protein binding: 99%- Poor CNS and urine penetration
- Vd: 0.39 L/kg- Protein binding: 99%- Poor CNS and urine penetration
Metabolism - No hepatic metabolism- No CYP involvement- Metabolism by slow chemical degradation
- Hepatic (COMT)- Weak substrate for CYP450
Elimination - Half-life : 24hrs- Via feces
- Half-life: 13 hrs- Via feces, > 90% unchanged
![Page 51: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/51.jpg)
Metabolism of echinocandinsAnidulafungin
ChemicalDegradation
HepaticMetabolism
Micafungin
EnzymaticBiotransformation
Renal Elimination
Caspofungin
HepaticMetabolism
ChemicalDegradation
![Page 52: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/52.jpg)
Anidulafungin Micafungin
Dose adjustments in hepatic insufficiency?
NoStudied in Child A,B,C: no increase in plasma levels
NoNot studied in Child C
Dose adjustments in renal insufficiency/dialysis?
No No
Drug interactions? Small increase in anidulafungin levels if combined with cyclosporine
Possibly mild inhibition of CYP3A with small increase in cyclosporine, sirolimus and nifedipin levels
![Page 53: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/53.jpg)
• Adverse reactions = mild• Infusion (histamine-mediated) related reactions
(especially at high infusion rates): flushing, pruritus, rash, urticaria
• Diarrhea, vomiting, nausea• Hepatic enzyme elevation: ALT, ALP, bilirubin
• In 5-10% of patients• Usually < 3-fold ULN
Anidulafungin - Micafungin: Tolerability and Safety
![Page 54: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/54.jpg)
Micafungin
http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/H-734-PI-en.pdf
Warning EMEA – risk hepatocellular tumor formation
• discontinuation if persistent elevation ALT/AST
• consider alternative in patients with severe liver function impairment or chronic liver diseases or concomitant hepatotoxic therapy
![Page 55: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/55.jpg)
Echinocandins: Pharmacodynamics
• Time-kill kinetics in vitro: • Concentration-dependent fungicidal against
Candida• Concentration-dependent fungistatic against
Aspergillus
• PK/PD relationship in vivo associated with effective therapy:• Cmax/MIC >4 (Candida spp.) • Cmax/MEC =10 (Aspergillus spp.)
Lewis, Curr Opinion Pharmacol 2007; 7:491-497
![Page 56: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/56.jpg)
Overzicht prijzen – patiënt 70 kgSpecialiteit Stofnaam Dosering Prijs 1 dag (€) Prijs 14 dagen
(€)Fungizone IV Amfotericine B 1 mg/kg 11.54 161
Abelcet IV Amfo B lipid complex 5 mg/kg 489 6848
Ambisome IV Amfo B liposomaal 3 mg/kg 889 12455
Diflucan IV fluconazole LD 800 mg - OD 400 mg 24 366
Diflucan PO fluconazole LD 800 mg - OD 400 mg 11 168
Vfend IV voriconazole LD 2x 6 mg/kg – OD 2x 4 mg/kg 626 9080
Vfend PO voriconazole LD 2x 6 mg/kg – OD 2x 4 mg/kg 84 1348
Noxafil PO posaconazole 2 x 400 mg 127 1781
Cancidas IV caspofungin LD 70 mg – OD 50 mg 483 7389
Ecalta IV anidulafungin LD 200 mg – OD 100 mg 429 6435
![Page 57: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/57.jpg)
Belgian situation
• Only Fungizone (AmB) en Diflucan(fluconazole) can be prescribed without reimbursement restrictions
• For all other antifungals: reimbursement criteria
• See www.riziv.be
![Page 58: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/58.jpg)
INVASIVE FUNGAL DISEASE: EORTC/MSG CRITERIA
De Pauw B et al., CID 2008: 1813-1821
PROVEN
POSSIBLE
PROBABLE Host factors
Host factors
Clinicalfeatures
Clinicalfeatures
Mycology
Sterile material microscopy and/or culture positive
+ +
+
![Page 59: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/59.jpg)
Host factors
Clinical features
Mycology
NeutropeniaaHSCTCorticosteroidsT cell immunosuppressants
CT/MRI signsClinical criteria
MicroscopyCultureAntigen (galactomannan, β-D-glucan)
![Page 60: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/60.jpg)
Treatment
• Invasive aspergillosis– First line: voriconazole– Second line: caspofungin/ liposomal amphotericin B/
posaconazole
• Candidemia– First line: fluconazole– Candida glabrata R to fluconazole, Candida krusei:
caspofungin or anidulafungin
![Page 61: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/61.jpg)
Antifungal resistance development
![Page 62: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/62.jpg)
Candida resistance• Development of resistance in C. albicans
– Mainly in HIV-infected patients during long term fluconazole treatment for oropharyngeal candidiasis (also resistant to itraconazole)
– Candidemia due to C. albicans resistant to fluconazole in cancer patients on azole prophylaxis remains limited
• Resistance to amphotericin B– C. lusitaniae: usually intrinsically resistant– C.guilliermondii: some isolates are intrinsically resistant– C. glabrata en C. krusei: probably less susceptible– Secondary resistance development is
![Page 63: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/63.jpg)
Etest
![Page 64: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/64.jpg)
Sensititre antifungal panel
Complete concentration range of different antifungal agents (amphotericinB, fluconazole, itraconazole,flucytosine, voriconazole, posaconazole, caspofungin, anidulafungin)
![Page 65: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/65.jpg)
Interpretative breakpoints CLSIBreakpoints established only for some organism-drug combinations
Antifungal agent S S-DD R
Fluconazole ≤ 8 µg/ml (≥ 19 mm) 16-32 µg/ml (15-18 mm) ≥ 64 µg/ml (≤ 14 mm)
Itraconazole ≤ 0,125 µg/ml 0,25-0,5 µg/ml ≥ 1 µg/ml
Voriconazole ≤ 1 µg/ml (≥ 17 mm) 2 µg/ml (14-16 mm) ≥ 4 µg/ml (≤ 13 mm)
Echinocandins (caspofungin, micafungin, anidulafungin)
S: MIC ≤ 2 µg/mLNS: MIC > 2 µg/mL
Azoles
![Page 66: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/66.jpg)
Clinical breakpoints EUCAST
Fluconazole 2/4 IE - 2/4 2/4
Voriconazole 0.125/0.125 IE - 0.125 0.125
Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
![Page 67: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/67.jpg)
Susceptibility patterns
Candida species Fluconazole Voriconazole Amphotericin B Candins
C. albicans S S S S
C. tropicalis S S S S
C. parapsilosis S S S S (tot I?)
C. glabrata S-DD tot R S tot I S tot I S
C. krusei R S tot I S tot I S
C. lusitaniae S S S of R S
Pappas et al., Clin Infect Dis, 2004: 38, 161-189.
![Page 68: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/68.jpg)
Resistance to fluconazole among Candida spp.
Pfaller et al, J Clin Microbiol 2007, 45: 1735-1745.
![Page 69: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/69.jpg)
Resistance to voriconazole among Candida spp.
Pfaller et al, J Clin Microbiol 2007, 45: 1735-1745.
![Page 70: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/70.jpg)
Candida resistance• Voriconazole
– 7191 Candida spp. from worldwide (2004-2007)– MIC (50)/MIC (90): 0.008/0.25 µg/mL (98% susceptible)
• Anidulafungin, caspofungin and micafungin– 5,346 invasive isolates from worldwide (2001-2006)– > 99% of isolates inhibited by < or = 2 µg/mL of all three
agents– No geographical differences in resistance– No significant change over time
Pfaller et al., J Clin Microbiol, 2006, 44: 760-763.
Diekema et al., Diagn Microbiol Infect Dis, 2009, 63: 233-236
![Page 71: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/71.jpg)
1945-1998
Multi-azole resistance in A. fumigatus
• MIC itraconazole > 16 mg/L• MIC voriconazole 2 - > 16 mg/L• MIC posaconazole 0,5 – 1,0 mg/L
2002-200712%
(10/81)
Verweij P et al., N Engl J Med 2007;356:1481-1483
0% (0/170)
![Page 72: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/72.jpg)
Azole resistance in A. fumigatus: The Netherlands
PLoS Med 2008;5:e219
R mechanisms: TR/L98H in 30 of 32 (94%) isolates
![Page 73: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/73.jpg)
NetherlandsNorwayPolandPortugal RussiaSpain SwedenSwitzerlandTaiwan TurkeyUK
AustraliaAustriaBelgiumBrazilChina DenmarkFinland France GermanyGreeceItaly
Global prevalence of resistance in Aspergillusfumigatus: SCARE study
![Page 74: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/74.jpg)
FUNGI DIFFER FROM BACTERIA WITH RESPECT TO THEIR TENDENCY TO DEVELOP RESISTANCE
• Few a priori resistant species and strains exist which could be selected
• Newer antifungal agents display a high affinity for the target
• Some fungi (e.g. C. albicans) are diploid
![Page 75: Antifungal therapy 230210.ppt [Read-Only] · Non-linear kinetics: saturable metabolism! • Small increases in dose result in exponential increases in blood levels • In children:](https://reader034.vdocuments.mx/reader034/viewer/2022042416/5f3189ffbcb32a63b70c2319/html5/thumbnails/75.jpg)
REASONS
• Mutations are often attended by a loss of fitness
• Genetic transfer of resistance from one fungus to another does not occur
• No drug modifying enzymes are known in fungi